GlassScriptPhysician profile
Jose E Roman-Candelaria
NPI 1710946520
$564.62
in general payments reported to CMS, 2019-2025
9 companies · $65.62 in 2025
The $65.62 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.24 · 2020: $60.57 · 2022: $30.52 · 2023: $142 · 2024: $182 · 2025: $65.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.30 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $64.90 | 2022-2023 | Verquvo |
| Inspire Medical Systems, INC. | $33.92 | 2023 | Inspire |
| Gilead Sciences, INC. | $30.11 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.96 | 2025 | Lifevest |
| Grifols USA, LLC | $15.00 | 2020 | |
| Boston Scientific Corporation | $14.04 | 2023 | |
| Opko Pharmaceuticals, LLC | $13.39 | 2023 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Roman-Candelaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.